ERYTECH Announces the A vailability of its H alf- Y ear F inancial R eport 202 1 Lyon (France) a nd Cambridge, MA (U.S.), Septembre 2 2 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 20 2 1 Conference call and webcast on Tuesday, September 21, 2021 at 8:30am EDT / 2:30pm CET TRYbeCA-1 Phase 3 trial of eryaspase in second-line metastatic pancreatic cancer fully enrolled since January
Lyon (France) and Cambridge, MA (U.S.), September 1 5 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second
ERYTECH to Present at the H.C. Wainwright 23 rd Annual Global Investment Conference Cambridge, MA (U.S.) and Lyon (France), September 6 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
Monthly information related to total number of voting rights and shares composing the share capital – August 3 1 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
Presentation on the lead product candidate eryaspase, L-asparaginase encapsulated in donor-derived red blood cells, featured by KOLs and also the Principal Investigators of the TRYbeCA-1 and rESPECT studies, respectively; Dr. Manuel Hidalgo Medina, M.D., Ph.D., Weill Cornell
ERYTECH to Participate in the Citi 16 th Annual BioPharma Conference Cambridge, MA (U.S.) and Lyon (France), August 30 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer Webinar on Wednesday, September 1 st @ 10am ET /4pm CET Cambridge, MA (U.S.) and Lyon (France), August 24 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company, leader in red
ERYTECH Granted U.S. FDA Fast Track Designation for E ryaspase in Hypersensitive ALL Fast Track d esignation for eryaspase underscores the need for new treatment options for patients who developed hypersensitivity reactions to pegylated asparaginase Cambridge, MA (U.S.) and Lyon (France), July 29
ERYTECH to Participate in the BTIG Virtual Biotechnology Conference Cambridge, MA (U.S.) and Lyon (France) , Ju ly 2 7 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
